Summary Box: FDA expands approval of J&J drug

Print
Email
|

Associated Press

Posted on December 10, 2012 at 4:00 PM

Updated Tuesday, Dec 11 at 12:01 PM

WASHINGTON (AP) — FDA OK: The Food and Drug Administration on Monday approved the drug Zytiga for a new group of prostate cancer patients who have not yet received chemotherapy.

FAMILIAR FACE: The FDA previously approved the pill from Johnson & Johnson for men with prostate cancer who have already taken the chemotherapy drug docetaxel.

HALTING HORMONES: Zytiga works be decreasing the male hormone testosterone, which spurs growth of prostate tumors.

Print
Email
|